Novo Nordisk A/S (BSP:N1VO34) Construction In Progress : R$28,434 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk A/S Construction In Progress?

Novo Nordisk A/S's quarterly construction in progress stayed the same from Jun. 2023 (R$0 Mil) to Sep. 2023 (R$0 Mil) but then increased from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$28,434 Mil).

Novo Nordisk A/S's annual construction in progress increased from Dec. 2021 (R$9,530 Mil) to Dec. 2022 (R$16,701 Mil) and increased from Dec. 2022 (R$16,701 Mil) to Dec. 2023 (R$28,434 Mil).

Novo Nordisk A/S Construction In Progress Historical Data

The historical data trend for Novo Nordisk A/S's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Construction In Progress Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

12,424.80

9,084.03

9,530.24

16,701.42

28,434.01

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial															16,701.42	-	-	-	28,434.01

Novo Nordisk A/S Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Novo Nordisk A/S (BSP:N1VO34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (BSP:N1VO34) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (BSP:N1VO34) Headlines

No Headlines